Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes.

@article{Musto2003EfficacyOA,
  title={Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes.},
  author={Pellegrino Musto and Antonietta Falcone and Grazia Sanpaolo and Carlo Bodenizza and Antonio La Sala and Gianni Perla and Angelo Michele Carella},
  journal={British journal of haematology},
  year={2003},
  volume={122 2},
  pages={269-71}
}
Thirteen patients with low-to-intermediate risk myelodysplastic syndrome (MDS) received recombinant erythropoietin (r-EPO) at the single, weekly dose of 40.000 U for at least 8 weeks. Five patients (38.4%) achieved a major erythroid response (increased haemoglobin levels > 2 g/dl and/or transfusion independence), which is currently maintained after 3-11 months, without modification of r-EPO dose. This study suggests that 40.000 U r-EPO given once a week may be at least as effective as the more… CONTINUE READING